HISUN(SH:600267) Shen Zhen Shang Bao·2026-01-16 11:57Core Viewpoint - Recently, Haizheng Pharmaceutical received a warning letter from the Zhejiang Securities Regulatory Bureau due to inaccuracies in financial disclosures from 2021 to 2024, which included corrections to revenue, costs, and investment income [1][2]. Financial Discrepancies - The company corrected its financial statements, resulting in a total reduction of 949 million yuan in revenue and 930 million yuan in costs for the years 2021 to 2023, while investment income was adjusted upwards by 18.8 million yuan [2]. - For 2024, the company reported an increase in revenue of 405 million yuan and costs of 395 million yuan, but a decrease in investment income of 10.3 million yuan [2]. Company Performance - For the first three quarters of 2025, Haizheng Pharmaceutical achieved a revenue of 7.923 billion yuan, reflecting a year-on-year growth of 0.61%, while net profit attributable to shareholders decreased by 10.55% to 461 million yuan [3]. - As of September 30, 2025, the company's debt-to-asset ratio was 42.84%, a decrease of 10.26% year-on-year, and accounts receivable amounted to 1.753 billion yuan, down 9.76% year-on-year [3]. Market Reaction - As of January 16, the company's stock price fell by 1.04%, closing at 10.50 yuan per share, with a total market capitalization of 12.59 billion yuan [4].